ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’

German biotech Tubulis has shared updated data from a phase 1 study of the antibody-drug conjugate (ADC) TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront in A The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule…

Source: FierceBiotech